logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Piramal Pharma Ltd

Piramal Pharma

Large Cap•5,476 Employees•IPO 2022
Current Price
₹151.87
-1.43 (-0.93%)Updated
NSE :PPLPHARMA
BSE :543635
Sector :Pharmaceuticals
Today's Range
₹151.37
₹151.87
union icon
₹154.81
52 Week Range
52W Low₹148.31
52W High₹240.95
₹151.87
union icon
Downside2.40%
Upside58.66%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹21,892.72 Cr
Market Cap
Total market value of company
P/E Ratio
-
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
3.13
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹-1.26
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
0.67%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
6.45%
ROCE
Return on Capital Employed. >15% is good
Net Margin
-1.84%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
-%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
-0.89%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
-5.44%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.60
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹61.35
Book Value
Net asset value per share
Dividend Yield
0.08%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
34.90%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

5 points
  • •Multifaceted business model across CDMO, hospital generics, and consumer healthcare.
  • •Global presence with 17 facilities and commercial reach in over 100 countries.

Weaknesses

5 points
  • •Low Return on Equity (1.11%) and Return on Capital Employed (6.45%).
  • •Reported negative quarterly profit (-₹93.5 crore) with a 5.44% decline.

Opportunities

4 points
  • •Pharmaceuticals sector experiencing robust growth driven by increasing healthcare expenditure.
  • •Potential for expansion into emerging markets and high-growth therapeutic areas.

Threats

5 points
  • •Intense competition from established players like Sun Pharma and Cipla.
  • •Strict and evolving regulatory policies could increase compliance costs and delays.

Segment-wise Financial Analysis

Financial Results

Balance Sheet

Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format

No Balance Sheet Data Available

Standalone annual data is not available for this symbol.
Try switching to Consolidated view.

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

No insider trading data available

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹160.88+₹9.01+5.93%
R3₹157.44+₹5.57+3.67%
R2₹156.12+₹4.25+2.80%
R1₹154.00+₹2.13+1.40%
PIVOT₹152.680.810.54%
CURRENT₹151.87--
S1₹143.68-₹8.19-5.39%
S2₹147.12-₹4.75-3.13%
S3₹149.24-₹2.63-1.73%
S4₹150.56-₹1.31-0.86%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
1.04M
(06 Mar 2026)
-57.0% vs avg
Delivery %
44.6%
(06 Mar 2026)
+6.4% vs avg
Avg Volume (20D)
2.41M
(06 Feb - 06 Mar)
20-day average
Avg Delivery %
38.2%
(06 Feb - 06 Mar)
Trend ↓
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Acutaas Chemicals Ltd
93.50 %
Highest Dividend Yield
Glaxosmithkline Pharmaceuticals Ltd
3.32 %

Peer Comparison

Company Name
ACUTAAS
Acutaas Chemicals Ltd
AJANTPHARM
Ajanta Pharma Ltd
APLLTD
Alembic Pharmaceuticals Ltd
ASTRAZEN
Astrazeneca Pharma India Ltd
COHANCE
Cohance Lifesciences Ltd
EMCURE
Emcure Pharmaceuticals Ltd
ERIS
ERIS Lifesciences Ltd
GLAND
Gland Pharma Ltd
GLAXO
Glaxosmithkline Pharmaceuticals Ltd
IPCALAB
Ipca Laboratories Ltd
JBCHEPHARM
J B Chemicals & Pharmaceuticals Ltd
JUBLPHARMA
Jubilant Pharmova Ltd
NATCOPHARM
Natco Pharma Ltd
NEULANDLAB
Neuland Laboratories Ltd
PFIZER
Pfizer Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd
WOCKPHARMA
Wockhardt Ltd

About

PPLPHARMA

Piramal Pharma Ltd

Piramal Pharma Limited (PPLPHARMA) is a multinational pharmaceutical company with a global reach, encompassing North America, Europe, Japan, India, and other international markets. Its core business revolves around the development, manufacturing, and distribution of a diverse portfolio of pharmaceutical products and services. This broad approach allows them to cater to a wide range of needs within the industry.

A significant portion of PPLPHARMA's operations involves contract development and manufacturing organization (CDMO) services. This segment offers a comprehensive suite of services across the entire drug lifecycle. This includes assistance with drug discovery, development, and the commercial manufacturing of both drug substances and finished products. This CDMO arm positions PPLPHARMA as a key partner for other pharmaceutical companies needing outsourced manufacturing and development capabilities.

Beyond CDMO services, PPLPHARMA maintains a robust internal portfolio of pharmaceutical products. A key area of focus is their complex hospital generics business. This division specializes in high-demand products like inhalation anesthetics, intrathecal therapies used in spasticity management, injectable pain and anesthesia medications, and other specialized generic and branded products. This segment targets the hospital and healthcare sector, providing essential medications.

In addition to its global and hospital-focused operations, PPLPHARMA also has a substantial presence in the Indian consumer healthcare market. This domestic segment offers a wide array of over-the-counter (OTC) products targeting various health needs. Their consumer healthcare portfolio includes analgesics (pain relievers), skincare products, vitamin and mineral supplements, children's wellness products, digestive aids, women's health products, and hygiene and protection items. This diversification within the Indian market allows them to tap into a broad consumer base.

In summary, PPLPHARMA's business model is built on a multifaceted approach. They function as both a CDMO providing services to other pharmaceutical companies and a direct producer and distributor of their own branded and generic pharmaceutical products across various segments, including the hospital market and the Indian consumer healthcare market. This strategic diversification minimizes reliance on any single sector and positions the company for sustained growth.

COMPANY FACTS - PPLPHARMA

Registered Address

Gr. Flr.,Piramal Ananta, Agastya Corporate Park,, Kamani Junction, LBS Marg, Kurla (West)

Mumbai

MAHARASHTRA

IN

Tel: 91223802300

Website:https://www.piramal.com/businesses/piramal-pharma/

Investor Relations:http://www.piramal.com/investor/piramal-pharma-limited/financial-reports/annual-reports/
Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Pharmaceuticals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 5,476

IPO Date: 19/10/2022

MANAGEMENT - PPLPHARMA

Ms. Nandini Piramal

Executive Chairman of the Board

Mr. Vivek Valsaraj

Chief Financial Officer, Executive Director

Ms. Tanya Sanish

Compliance Officer, Company Secretary

Mr. Peter Deyoung

Executive Director, Chief Executive Officer of Global Pharma

Mr. Amit Jain

Additional Non-Executive Non-Independent Director

Ms. Nathalie Leitch

Non-Executive Non- Independent Director

Mr. Sridhar Gorthi

Non-Executive Independent Director

Mr. Jairaj Purandare

Non-Executive Independent Director

Mr. S. Ramadorai

Non-Executive Independent Director

Ms. Vibha Rishi

Non-Executive Independent Director

Mr. Peter Stevenson

Non-Executive Independent Director

Investor Questions Answered

Piramal Pharma Ltd (PPLPHARMA) Stock FAQs

Get answers to the most common questions about Piramal Pharma Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Piramal Pharma Ltd (PPLPHARMA) is ₹151.87. Today, the stock has declined by ₹1.43 (0.93%), trading in a range of ₹151.37 to ₹154.81. The stock opened at ₹153 with a trading volume of 10,38,728 shares.
Piramal Pharma Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹21,892.72 crores, P/E ratio of 0.00, ROE of 0.67%, and ROCE of 6.45%. The dividend yield stands at 0.08%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Piramal Pharma Ltd (PPLPHARMA) is ₹240.95, while the 52-week low is ₹148.31. Currently trading at ₹151.87, the stock is 3.8% away from its 52-week low and 37.0% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Piramal Pharma Ltd stock at ₹151.87 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of N/A. Today's performance shows a loss of 0.93%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Piramal Pharma Ltd offers a dividend yield of 0.08%, which means for every ₹100 invested at the current price of ₹151.87, you can expect to receive approximately ₹0.08 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Piramal Pharma Ltd's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: N/A, ROE: 0.67%, ROCE: 6.45%, Dividend Yield: 0.08%, EPS: ₹-1.26, Book Value: ₹61.35, Debt-to-Equity: 0.60, and Current Ratio: N/A. The company's market cap stands at ₹21,892.72 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Piramal Pharma Ltd stock opened at ₹153 and is currently trading at ₹151.87, showing a decline of ₹1.43 (0.93%). The intraday high is ₹154.81 and low is ₹151.37. The trading volume stands at 10,38,728 shares, indicating strong market participation today.
Piramal Pharma Ltd has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹-1.26, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
Piramal Pharma Ltd has a market capitalization of ₹21,892.72 crores, making it a mid-cap company. Market cap is calculated by multiplying the current stock price (₹151.87) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Piramal Pharma Ltd has a book value of ₹61.35 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹151.87, which is 147.5% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Piramal Pharma Ltd has a Return on Equity (ROE) of 0.67% and Return on Capital Employed (ROCE) of 6.45%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Piramal Pharma Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Piramal Pharma Ltd has a debt-to-equity ratio of 0.60, which measures the company's financial leverage by comparing total debt to shareholders' equity. This moderate ratio indicates balanced use of debt and equity. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Piramal Pharma Ltd has an Earnings Per Share (EPS) of ₹-1.26, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹151.87 and P/E ratio of 0.00, investors are paying 0.00 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Piramal Pharma Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Piramal Pharma Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Piramal Pharma Ltd stock, consider: 1) Fundamental Analysis - Review P/E (0.00), ROE (0.67%), debt-to-equity (0.60), and growth rates. 2) Technical Analysis - Check 52-week range (₹148.31 - ₹240.95), moving averages, and chart patterns. 3) Valuation - Compare current price (₹151.87) with book value (₹61.35) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Piramal Pharma Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹151.87 is 1419x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Piramal Pharma Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹148.31 - ₹240.95). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.60 indicates leverage. 4) Liquidity Risk - Based on trading volume of 10,38,728 shares. 5) Valuation Risk - P/E of 0.00 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Piramal Pharma Ltd operates in the industry with key metrics: P/E ratio of 0.00, ROE of 0.67%, market cap of ₹21,892.72 crores, and dividend yield of 0.08%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.60), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Piramal Pharma Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹151.87, with a 52-week range of ₹148.31 to ₹240.95. Based on fundamentals like P/E (0.00), ROE (0.67%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Piramal Pharma Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹151.87. 2) Fundamental Deterioration - Declining ROE (currently 0.67%), increasing debt (D/E: 0.60), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Piramal Pharma Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.08%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.